In a filing with the US financial regulator, German mRNA specialist BioNTech (Nasdaq: BNTX) has noted the lifting of a partial clinical hold on its PRESERVE-003 trial.
BioNTech is working with OncoC4 on development of the molecule, gotistobart, as a possible monotherapy for metastatic non-small cell lung cancer (NSCLC) after checkpoint blockers have failed.
The trial was originally paused in October due to "varying results" between patients with squamous and non-squamous NSCLC, and will now continue enrollment exclusively for patients with squamous NSCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze